Short Summary
Immunovative Therapies Ltd. appealed a rejection order dated December 4, 2018, concerning its patent application for 'TH1 VACCINATION PRIMING FOR ACTIVE IMMUNOTHERAPY'. The appellant argued that the rejection based on Section 3(d) and (i) was incorrect, as the invention relates to therapeutic vaccine methods using allogeneic CD3/CD28 cross-linked Thl memory cells.
Detailed Summary
In the high-stakes world of cancer immunotherapy, where every new method could potentially save thousands of lives, the line between a patentable invention and an unpatentable discovery is razor-thin. For one biotech innovator, that line became the center of a legal battle that could reshape how therapeutic vaccine methods are protected. The case of Immunovative Therapies Ltd. versus the Controller of Patents raises a critical question for founders and IP professionals alike: when does a novel therapeutic method cross the threshold from a mere discovery into a genuine, patentable invention?
Immunovative Therapies Ltd., a company focused on developing advanced immunotherapies, filed a patent application for an invention titled 'TH1 VACCINATION PRIMING FOR ACTIVE IMMUNOTHERAPY.' The invention centered on therapeutic vaccine methods using allogeneic CD3/CD28 cross-linked Th1 memory cells — a sophisticated approach aimed at priming the immune system to fight cancer. On December 4, 2018, the Controller of Patents issued a rejection order against this application, citing Section 3(d) and Section 3(i) of the Patents Act as grounds for refusal. These sections are notoriously stringent barriers in patent law, particularly for pharmaceutical and biotechnological inventions. Section 3(d) typically bars patents on new forms of known substances unless they demonstrate significantly enhanced efficacy, while Section 3(i) relates to methods of treatment of humans and animals. Faced with this rejection, Immunovative Therapies Ltd. chose to fight back, filing an appeal that came before the court on April 11, 2023.
The core of the legal friction lay in whether Immunovative Therapies' invention qualified as a patentable subject matter under Indian patent law. The Controller of Patents had taken the position that the application fell foul of Section 3(d) and Section 3(i), effectively arguing that the therapeutic vaccine method using allogeneic CD3/CD28 cross-linked Th1 memory cells did not meet the statutory requirements for patentability. Immunovative Therapies Ltd. countered forcefully, arguing that the rejection was incorrect. The appellant maintained that the invention was not a mere discovery or a new form of a known substance, but rather a genuine therapeutic vaccine method with distinct clinical applications. The company positioned its innovation as a meaningful advancement in active immunotherapy — one that deserved the protection of a patent. The legal tension thus centered on a fundamental question: does the use of known biological cells in a novel therapeutic combination constitute a patentable invention, or does it fall within the exclusions carved out by Sections 3(d) and 3(i)?
As of the most recent proceedings on April 11, 2023, the case remains pending. The court has not yet issued a final ruling on whether Immunovative Therapies Ltd.'s patent application for 'TH1 VACCINATION PRIMING FOR ACTIVE IMMUNOTHERAPY' should be allowed or whether the rejection under Section 3(d) and Section 3(i) will be upheld. The outcome of this appeal will carry significant implications for how therapeutic vaccine methods — particularly those involving allogeneic cell-based immunotherapies — are evaluated for patentability in India.
For founders and IP professionals in the biotech and pharmaceutical space, this case underscores the importance of carefully framing patent applications to address the specific exclusions under Section 3(d) and
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court - Orders. Understanding the court's reasoning in Immunovative Therapies Ltd. vs The Controller Of Patents is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Martinswerk GmbhvsThe Assistant Controller of Patents and Designs, Government of India
Martinswerk Gmbh appealed the rejection of its product patent application for novel aluminum hydroxide flame retardants. The appeal argued that the Patent Controller repeatedly shifted and reverted between different limbs of Section 3(d) without providing a consistent or fair hearing process. The High Court found merit in these submissions.
Dow Agrosciences LlcvsThe Controller Of Patents
Dow Agrosciences LLC challenged the refusal of its patent application, 'Stabilized Agricultural Oil Dispersions,' citing errors and inaccuracies in the Controller's objections. The appellant argued that key prior art documents were wrongly cited or misinterpreted, particularly regarding thermal stability claims. Recognizing significant procedural flaws and incorrect references in the impugned order, the Delhi High Court allowed the appeal and remanded the matter back to the Patent Office for a fresh examination.
M/s.Lyca ProductionsvsJ.Manimaran
M/s. Lyca Productions filed an appeal seeking an injunction against J. Manimaran (and others) for allegedly infringing on their film title 'KARU', which they claimed to have registered with a Film Producers Guild in 2011. The core dispute revolved around whether this guild registration conferred exclusive rights over the title, especially when the opposing party had also invested heavily and was readying its release. The Madras High Court ultimately allowed the appeal, ruling that such guild registration does not grant exclusive use of the title without statutory backing.
Parijat Industries India Private LimitedvsDeputy Controller Of Patents And Designs & Anr.
Parijat Industries appealed against an order by the Deputy Controller of Patents and Designs which had revoked its Indian Patent No. 372550 based on grounds under Section 25(2)(b), (e), (f) and (g). The High Court found that the reasoning provided in the Impugned Order was inadequate and did not meet judicial standards.
Jaypee Brothers Medical Publisher Pvt LtdvsRama Krishna Books
The Delhi High Court granted an ex parte ad interim injunction in favor of Jaypee Brothers Medical Publisher Pvt Ltd against Rama Krishna Books. The publisher alleged that the defendant was selling substandard, infringing copies of their medical textbooks while also misusing their registered trademarks. The court found a prima facie case for infringement and ruled that granting the injunction was necessary to prevent irreparable harm to the plaintiff's business interests in the specialized medical publishing market.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.